

AQ



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(5) International Patent Classification 5 : A61K 37/02, 37/36, C12N 15/00 C12N 15/12, 15/18		(11) International Publication Number: WO 93/23068 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/US93/04550 (22) International Filing Date: 13 May 1993 (13.05.93)	(74) Agent: HANSON, Norman, D.; Felfe & Lynch, 805 Third Avenue, New York, NY 10022 (US).	
(30) Priority date: 07/883,949 US 07/977,234	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH (US/US); 1345 Avenue of the Americas, New York, NY 10105 (US).	Published With international search report. With amended claims.	
(72) Inventors: VASSBOTN, Flemming, S.; ANDERSSON, Maria; S-751 24 Uppsala (SE); BACKSTROM, Gudrun; S-751 25 Uppsala (SE); ENGSTROM, Ulla; S-751 24 Uppsala (SE); HELDIN, Carl-Heinrik; S-751 25 Uppsala (SE); HELLMANN, Ulf; OSTMAN, Arne; WESTERMARK, Bengt; S-751 24 Uppsala (SE).		
(54) Title: PLATELET DERIVED GROWTH FACTOR ANTAGONISTS		
SIEEAVPAVCKTRTVIYEIPRSQVDPSTANFLIWP sp4 -----@----- sp3 ----- PCVEVXRCTGCCNTSSVKCQPSRVHRSVKVAKVE sp1 -----@-----@----- -#-- YVRKKPKLKEVQVRLBEHLECACATSLNPDYREE sp2 @ -@----- DTGRPRESGKKRKRRLKPKPT		
(57) Abstract <p>The invention describes antagonists for PDGF. The antagonists contain amino acids, and may be monomers or dimers. Especially preferred are dimers which bind the PDGF receptors, but prevent dimerization of the bound receptors. Dimerization is necessary for PDGF effect, hence the antagonistic effect. Also described are nucleic acid sequences for making the antagonists, as well as cell lines transfected with the material. The figure sets forth amino acid sequences for peptides eluted from PDGF-A HPLC experiments.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlet publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BC	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CC	Central African Republic	JP	Japan	RU	Russian Federation
CH	Switzerland	KR	Republic of Korea	SD	Sudan
CI	Cote d'Ivoire	KZ	Kazakhstan	SE	Sweden
CM	Cameroun	LI	Liechtenstein	SK	Slovak Republic
CS	Czechoslovakia	LK	Sri Lanka	SN	Senegal
CZ	Czech Republic	LU	Luxembourg	SU	Soviet Union
DE	Germany	MC	Monaco	TD	Chad
DK	Denmark	MG	Madagascar	TG	Togo
ES	Spain	ML	Mali	UA	Ukraine
FI	Finland	MN	Mongolia	US	United States of America
				VN	Viet Nam

PLATELET DERIVED GROWTH FACTOR ANTAGONISTS

RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Serial Number 883,949 filed on May 15, 1992.

FIELD OF THE INVENTION

This invention relates to antagonists of the molecule known as platelet derived growth factor, or "PDGF". More particularly, it refers to amino acid containing antagonists, both monomers and dimers, for PDGF-BB. Also described are various nucleic acid based materials useful in preparing the antagonists, as well as uses therefor.

BACKGROUND AND PRIOR ART

PDGF was first recognized as a component of platelet α granules, which had growth promoting activity for smooth muscle cells and fibroblasts (Heldin and Westermark, Cell Regul 1: 555-566 (7-90)). It has also been implicated in the stimulation of connective tissue - derived cells in vitro (Östman et al., J. Biol. Chem. 263(31): 16202-16208 (11-88)), as the major mitogenic protein for mesenchymal cells (Murray et al., U.S. Patent Nos. 4,889,919 and 4,845,075), and as an inducer of cell multiplication and DNA synthesis in cultured muscle cells, fibroblasts and glial cells (Kelly et al, PCT Application WO90/14425 (11-29-90)). It has also been shown to be involved in the wound healing response (Ross et al., N. Eng. J. Med. 295: 369 (1976)), and may be involved in a causative role for the development of proliferative lesions of atherosclerosis (Ross) supra. Others have suggested that this molecule may be a mediator of tumor development as well as in nonmalignant proliferative disorders (Heldin et al., supra).

The PDGF molecule has been very well characterized. It is known to exist as a heterodimer of an "A" chain and a "B" chain, connected to each other via disulphide bonds. The dimer, sometimes referred to as "PDGF-AB", has a molecular mass of about 30 KDa. Amino acid sequences are known for both the A and B chains, as shown, e.g., by Murray et al., U.S. Patent Nos. 4,889,919 and 4,845,075, the disclosures of which

are incorporated by reference. The mature chains contain slightly more than 100 amino acids, and are about 60% homologous. Heldin et al., supra.

Dimers PDGF-AA and PDGF-BB have been produced via recombinant means, and have also been isolated from natural sources (see Murray et al., supra; Heldin et al., supra). The various dimers, or "isoforms" differ in functional properties and secretory behavior.

The mechanism by which PDGF acts on cells has received intensive scrutiny, and it has been established that there are two receptors for PDGF, the " α " and " β " receptors. The α receptor binds all isoforms, whereas the β receptor does not bind PDGF-AA, binds PDGF-BB with low affinity, and PDGF-BB with high affinity (Heldin et al., supra; Östman et al., supra). The α receptor is synthesized as a 140 KDa precursor protein which matures to one of 170 KDa, and the β receptor is recognized as a precursor of 160 KDa, and a mature molecule of 180 KDa. cDNA for both receptors have also been isolated (Heldin et al., supra; Kelly et al., supra).

The receptors both comprise five immunoglobulin like domains (extracellular portion), and intracellular portions containing protein tyrosine kinase domains with characteristic insert sequences which have no homology to kinase domains (Yarden et al., Nature 323: 226-232 (1986); Matsui et al., Science 243: 800-803 (1989); Claesson-Welsh et al., PNAS 86: 4917-4921 (1989). When PDGF binds to these receptors, dimerization of the receptor molecules is induced, followed by kinase activation and autophosphorylation of the receptors (Heldin et al., J. Biol. Chem. 264: 8905-8912 (1989); Seifert et al., J. Biol. Chem. 264: 8771-8778 (1989); Bishayee et al., J. Biol. Chem. 264: 11699-11705 (1989)).

The diverse actions of PDGF and its suggested involvement in disease states would indicate that the use of agonists and antagonists may be useful in defining the action of PDGF and of alleviating some of the disorders. These molecules, using the definitions employed by Kelly et al., supra, either mimic the effect of PDGF (agonists), or block the interaction of

receptor and ligand (antagonists).

The art has long recognized that agonists and antagonists for various materials exist, and Kelly et al., via their discussion, de facto assumes that these exist for PDGF. Review of the literature indicates, however, that no proteinaceous agonists and antagonists to PDGF are taught. For the reasons described supra, it would be desirable to have such material available.

The two patents to Murray et al., cited supra discuss potential amino acid substitution of cysteine residues in the monomeric chains, provided that these substitutions do not destroy the biological activity of the molecules. The '919 patent generally teaches modifications of PDGF AA molecules. Neither reference teaches that modified dimers of PDGF have antagonistic activity against wild type PDGF.

It has now been found that substitutions within the amino acid chain of PDGF monomers leads to the production of antagonists to PDGF-BB. As PDGF-BB is implicated in the transformation of cells, the antagonists have value in a therapeutic context, as well as in various other milieux, as described in the disclosure which follows.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows HPLC purification of peptide 16T, which is elaborated upon in the examples.

Figure 2 shows competitor activity of peptides on ¹²⁵I-PDGF-AA binding to α receptors.

Figures 3A, 3B and 3C depicts competitive activity of various HPLC purified PDGF derived peptides on binding of various ligands to PDGF receptors.

Figure 4 presents data showing inhibiting effect of various PDGF derived peptides on ¹²⁵I-labeled Pgf-AA internalization and degradation.

Figure 5 shows the inhibition of receptor dimerization and autophosphorylation by peptide 16T.

Figure 6A shows the effect of the reducing agent dithiothreitol ("DTT") on dimeric PDGF-AA.

Figure 6B shows the elution of monomeric materials following

reduction of dimeric PDGF.

Figure 7A shows HPLC information secured from proteolytically degraded, partially reduced monomeric PDGF-A.

Figure 7B sets forth amino acid sequences for the peptides eluted from the HPLC experiments of Figure 7A.

Figures 8A and 8B show analysis of immunoprecipitated, conditioned medium following labelling with [³⁵S]-cysteine.

Figure 9 shows experiments involving cell growth and competition between 125-PDGF-BB and serial dilutions of peptides.

Figures 10A and 10B show SDS-PAGE immunoprecipitation studies using PDGF B derivatives (10A) and the effect of derivatives on dimerization (10B).

Figure 11A shows studies on PDGF-AA dimer formation.

Figure 11B shows receptor competing activity of single bonded dimers

Figure 12, labelled PRIOR ART, is the restriction map of plasmid pSV7d.

Figure 13 generally shows the immunoprecipitation of PDGF-A and the mutant PDGF-O following expression in COS cells.

Figure 14 depicts the results of binding assays using the mutant PDGF-O and PDGF-A.

Figure 15 presents data concerning the immunoprecipitation of PDGF-B producing cells following transfection with PDGF-O DNA.

Figure 16 shows the production of PDGF-OB heterodimers by pSV7d-PDGF-O transfected sis3T3 cells.

Figure 17 compares the morphology of sis3T3 PDGF-O producers to non producers.

Figure 18 presents, in graph form, data regarding the effect of PDGF-O on sis3T3 proliferation.

Figure 19 shows the effect of PDGF-O on colony formation of sis3T3 cells.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Examples 1

In order to test for receptor binding, cultures of human

foreskin fibroblast cell line AG1518 (obtained from the Human Mutant Cell Repository), were grown to confluence in Ham's F-12 medium containing 10% newborn calf serum. Those cells which were to be used in analysis of PDGF- β receptor binding were preincubated for 60 minutes at 37°C in 0.5 ml/well of Ham's F-12 medium, supplemented with 1 mg/ml of bovine serum albumin (BSA), and 50 ng/ml of PDGF-AA. This combination down regulates PDGF- α receptor, as per Claesson-Welsh et al., J. Biol. Chem. 264: 1742-1747 (1989).

Cells were prepared for receptor binding analyses by washing with ice cold binding buffer (phosphate buffered saline with 0.9 mM CaCl₂, 0.49 mM MgSO₄ and 1 mg/ml BSA). The cells were then incubated on ice for 90 minutes with different concentrations (0-100 ug/ml) of synthetic peptides (listed in Table 1, *infra*), in 0.5 ml of binding buffer per well. This was followed by addition of ¹²⁵I labelled PDGF-AA, PDGF-BB, or EGF. The labelled ligand was added and then incubated for 60 minutes at 0°C, after which the cells were washed five times with ice cold binding buffer. The washed cells were then lysed for 60 minutes at room temperature in a lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Tris-HCl, pH 7.5). Solubilized radioactivity was determined in a gamma counter. Competing activities of synthetic peptides were compared to standard curves, using unlabelled ligand.

The peptides used were all derived from the amino acid sequence of the PDGF- β chains. Amino acid designations are in accordance with those provided by Betsholtz et al., Nature 320: 695-699 (1986), the disclosure of which is incorporated by reference. This paper gives the complete, unprocessed sequence for both the A chain and the B chain of PDGF. It is to be understood that when numbering is used herein (e.g., "Cys 123"), this refers to the complete, unprocessed sequence of the monomer; however when position is used to describe the placement of cysteine groups, e.g., "second cysteine", this refers to the processed molecule. The first amino acid in the processed PDGF A chain is serine, and is found at position 87. of the unprocessed molecule. The first amino acid in PDGF-

B chain is also serine, and is found at position 82 of the unprocessed chain. Unprocessed PDGF A is 211 amino acids long; unprocessed PDGF B is 241 amino acids long.

Table 1

Synthesis Peptides

Peptide Number	Portion of PDGF-B amino acid sequence
1	155-180, but Cys at 178 changed to Ser
2	141-163
3	142-163
4	142-179
5	111-140, but Cys at 124, 133 and 134 changed to Ser
6	116-127
7	116-127 and 147-163
8	121-127 and 147-163
9	116-127 and 147-157
10	116-127 and 147-163
11	116-124 and 152-163
12	116-123 and 152-163
13	116-123 and 153-161
14	116-121 and 153-161
15	116-119 and 154-162
16	116-121 and 157-163
17	107-127 and 152-163
18	98-106 and 116-127 and 152-163
*19T	112-121 and 157-163
*16	116-121 and 157-163
*16T	116-121 and 157-163 but tryptophan is changed to thioanisole
*16NPS	116-121 and 157-163, but tryptophan is modified by nitrophenyl sulfonyl
*20	Glu Ala Phe Ile Lys Trp Leu Val Arg Asn Lys Val Pro
*20T	Glu Ala Phe Ile Lys Trp Leu Val Arg Asn Lys Val Pro, but tryptophan is modified by thioanisole

In Table 1, an asterisk means homogeneous peptide was used. Otherwise, crude peptide was used. An explanation of homogeneous and crude peptide is presented *infra*.

The ability of the peptides to inhibit binding of PDGF-BB was measured in terms of how much peptide was needed to decrease binding by 50%. In Table 2, "+++" means < 30 μ M;

"++" from 30-60 μ M; "+" 60-150 μ M; and "-" > 150 μ M.

Table 2

Ability To Compete With PDGF-BB For Binding

Inhibitory Activity

Peptide	Inhibitory Activity
1	-
2	-
3	-
4	++
5	+
6	+
7	++
8	-
9	+++
10	++
11	+++
12	+
13	+
14	+
15	-
16	+++
17	+++
18	+++
*19T	+++
*16	-
*16T	+++
*16NPS	+++
*20	-
*20T	-

While only results for PDGF-BB inhibition are shown, similar results were obtained when PDGF-AA was used.

The peptides tested were all derived from the region spanning amino acids 97-180 ("Cys-Cys") of PDGF-B, because this region has been found to be sufficient to impart the full biological activity of the molecule. (King et al., Proc. Natl. Acad. Sci. USA 82: 5295-5299 (1985)).

Co-linear peptides 1-6 yielded only limited inhibition. The weak inhibition secured with peptides 4 and 5 suggested that

the combination of these two regions of the sequence might be more effective.

Peptide 7, 29 amino acids long and containing 12 N-terminal region and 17 C-terminal amino acids, competed efficiently for both receptors, with 50% competition at about 6 μ M. In view of these results, additional peptides were prepared and tested so as to narrow the epitopes involved. Peptide 8, in which the five most N-terminal amino acids of peptide 7 were deleted, was nearly devoid of activity, as was peptide 9, lacking the six most C-terminal amino acids. When three amino acids at the N-terminal side of the epitopic junction were removed (peptide 10), or five C-terminal amino acids were removed (peptide 11), the effect on activity was lessened.

Attempts to further define the two epitopes led to the generation of peptide 16, which has amino acid sequence

ANFLWELVRKKP

and maintained most of the receptor competing activity. Removal of two junction amino acids, however, yielded an insoluble peptide which could not be analyzed. Extensions at the NH₂-terminus (peptides 17-19), did not increase activity. The conclusion reached from these experiments is that a peptide, 13 amino acids long and containing portions of two regions of B chain of PDGF is an efficient competitor of PDGF-AA and PDGF-BB binding to the α and β receptors.

Example 2

The peptides used in the experiments of Example 1 had been prepared using t-Boc chemistry using a peptide synthesizer. They were cleaved from polymeric supports via incubation with HF at 0°C for 60 minutes with 8% anisole and 4% methyl ethylsulfide as scavengers. When peptides contained tryptophan, 3% thioanisole was added. These preparations were crude formulations.

The interesting results secured with peptide 16 suggested experiments using purified material. To that end, peptide 16 was purified via reversed phase HPLC on a Vydac C18 column (10 x 250 mm) using a 30 minutes gradient of 10-90% acetonitrile in 0.1% trifluoroacetic acid. Peptide was identified and

analyzed using ²⁵²Cf plasma desorption mass spectrometry, as per Sundqvist et al., Mass Spectrometry Rev. 4: 421-460 (1985). Each fraction from the HPLC was then analyzed, both via the methodology described supra, and via mass spectrometry.

Surprisingly, the component with the expected molecular mass of peptide 16 (¹⁶Da in Tables 1 and 2), had very low activity compared to other HPLC components. A component showing a molecular mass of 122 Da, which is greater than that of peptide 16, showed higher activity. Analysis of the HPLC work led to the conclusion that thioanisole had been attached to tryptophan in peptide 16 during mass spectrometry. To secure larger amounts of this peptide, referred to as "16T", higher concentrations of thioanisole were used in the deprotection step. HPLC purification is shown in Figure 1, and the competitor activity of the various HPLC fractions are shown in Figure 2. Table 3, which follows, presents proposed structures and masses of ions determined by HPLC.

Table 3. Mass spectrometric analysis of fractions collected during HPLC purification (Fig. 2B) of Peptide 16.

Fraction	Observed m/z	Proposed molecule (Expected value of m/z within parentheses)
1	1452.6	M-Phe (1453.7)
	1581.6	M-Nitrl (1582.9)
2	1601.0	M (1600.9)
	1581.5	M-Nitrl (1582.9)
3	1599.2	M (1600.9)
4	1485.8	M-Asn (1486.8)
	1599.2	M (1600.9)
5	1644.9	
	1644.8	
	1560.0	
6	1574.0	M122-Phe (1575.9)
	1654.9	M + tBu (1657.0)
7	1708.1	M122-Nitrl (1705.8)
8	1721.2	M122 (1723.1)
9	1754.0	M + Tos (1755.1)
	1722.8	M122 (1723.1)
	1689.9	M + OBzl (1691.0)
	1651.1	M122 - Ala (1652.0)
	1594.2	M122 - Lys/Glu (1594.1/1593.9)
10	1724.7	M122 (1723.1)
	1608.5	M122 - Asn (1609.0)
11	1763.9	M122-Nitrl + tBu (1761.2)
12	1778.1	M122 + tBu (1779.2)
13	1778.1	M122 + tBu (1779.2)
14	1846.9	M122 + Clz (1847.6)
	1875.8	M122 + Tos (1877.3)
15	1847.0	M122 + Clz (1847.6)

Abbreviations: M, Peptide 16; M122, Peptide 16T; Nitrl, dehydrated asparagine; Bu, *tert*-Buryl; Tos, 4-toluenesulfonyl; OBzl, Benzyl ester; Clz, 2-chlorobenzoyloxy-carbonyl;

Example 3

To test the hypothesis that modification of tryptophan would potentiate activity, peptide 16 was incubated with 2-nitrophenyl-sulfonyl chloride (NPS-Cl), which is known to react with tryptophan (see Scoffone et al., Biochem. 7: 971-979 (1968)). The resulting derivative "16NPS", also had increased activity as an antagonist as compared to peptide 16.

In comparative experiments, depicted in Figures 3A, 3B and 3C, peptides 16 and 16T were tested for competitive activity for both 125 I-PDGF-AA and 125 I-PDGF-BB (α and β receptors). The figures show that while peptide 16 had a marginal effect, 16T was an effective competitor for both PDGF-AA and PDGF-BB. Forty-four ug/ml (26 μ M), and 57 ug/ml (33 μ M) of peptide 16T gave 50% competition for receptor binding to 125 I-PDGF-AA and 125 I-PDGF-BB, respectively.

A control was carried out using peptides with randomized amino acid sequence - i.e., peptides 20 and 20T, the latter carrying the thioanisole modification on tryptophan. As shown in Figures 2A, 2B and 2C, the peptides did not compete for binding. The conclusion which must be reached from these experiments is that the amino acid sequence and a tryptophan modification are important for competitive behavior.

Figure 3C shows that none of peptides 16, 16T, 20 and 20T compete for binding of 125 I-EGF to the EGF receptor. The peptide 16T thus is specific for PDGF receptor competition.

Example 4

The possible role of peptide 16T as an antagonist for PDGF activity *in vivo* was investigated. Following the methodology of Besholtz et al., J. Cell Physiol 118: 203-210 (1984), the disclosure of which is incorporated by reference, [3 H] thymidine incorporation by human fibroblasts in the presence of various peptides was studied. Table IV shows these results *infra*. Table IV shows that PDGF-BB and EGF stimulated the incorporation of [3 H] thymidine into fibroblasts 4- and 5-fold, respectively. PDGF-AA gave lower stimulation, which is consistent with the results obtained by Nisler et al., Cell 52: 791-799 (1988). The peptides 16 and 16T did inhibit PDGF-

13

AA and PDGF-BB induced mitogenicity, but also EGF induced mitogenicity. This indicates that peptides 16 and 16T did not operate solely on the level of competition for receptor; rather, an additional mechanism is involved. Peptide 20, i.e., the control, showed a minor effect on ligand stimulated [³H] thymidine incorporation, while peptide 20T showed some non specific inhibition activity. Peptide 16T was more efficient than peptide 16, and lowered background incorporation of [³H] thymidine dramatically.

10

Table 4. Effect of the Peptides 16, 16T, 20 and 20T on ligand stimulated [³H]thymidine incorporation in human foreskin fibroblasts. Figures represent mean of duplicates.

Peptide	Ligand used for stimulation			
	Control (cpm)	PDGF-AA (cpm)	PDGF-BB (cpm)	EGF (cpm)
Control	483	677	1918	2591
Peptide 16	241	242	281	216
Peptide 20	348	335	1541	2059
Peptide 16T	46	90	102	119
Peptide 20T	456	489	836	515

20

Example 5

Further experiments were carried out to study the effect of the peptides on intact cells; specifically, inhibition of ligand degradation was studied.

25

To do this, confluent human foreskin fibroblast cells in 12 well dishes were washed once with 1.0 ml of Ham's F-12 medium, supplemented with 1 mg/ml BSA. As described *supra*, those cells to be tested later for ¹²⁵I-PDGF-BB degradation were preincubated with PDGF-AA to downregulate α receptors. Cells were then incubated with different concentrations of each of peptides 16, 16T, 20 and 20T together with ¹²⁵I labelled PDGF-AA, PDGF-BB or EGF in 0.5 ml/well Ham's F-12 medium containing 1 mg/ml BSA. The mixtures were incubated for four hours at 37°C, the incubation medium was removed, and then precipitated

35

14

with trichloroacetic acid at 10% final concentration. The amount of trichloroacetic acid non-precipitable radioactivity in cell culture medium was taken as an estimate of ligand degradation - i.e., it represents ligand that had been internalized, degraded and released into the medium in the form of free ¹²⁵I, ¹²⁵I-Tyr, or low molecular weight fragments. This parameter was defined after four hours of incubation at 37°C.

Figure 4 shows that all peptides showed some inhibitory activity with respect to ¹²⁵I-PDGF-AA degradation, with peptide 16T being the most effective. The effect on PDGF-BB degradation was lower, with peptide 16T being the most potent. All peptides inhibited ¹²⁵I-EGF degradation, but all peptides showed a similar activity.

These results show that peptide 16T has an effect on cells which is a combination of specific inhibition at PDGF receptor level and an effect inside the cell which is not PDGF specific.

Example 6

The foregoing results show that peptide 16T interacts with both the α and β receptors. As binding of PDGF to receptors leads to receptor internalization and downregulation, investigations were carried out to determine whether the interaction of PDGF and peptide 16T led to the internalization and downregulation of receptors. To test this, confluent cells, as described *supra*, were washed once with binding buffer at 37°C, followed by incubation with different concentrations of synthetic peptide (0.5 ml of PBS containing 1 mg/ml BSA). Following this, the cells were incubated at 37°C for four hours, followed by washing with 1 ml of ice cold buffer consisting of 20 mM Na-acetate, 150 mM NaCl, 0.2% BSA adjusted to pH 3.7 with acetic acid. The cells were then incubated for 10 minutes on ice in buffer, followed by two washings with 1 ml binding buffer, at pH 7.4. The number of PDGF receptors on the cell surface was estimated by incubation with ¹²⁵I-PDGF-BB (-50,000 cpm) in 0.5 ml binding buffer for 60 minutes on ice, followed by washing, lysis and

35

15

determination of cell bound radioactivity.

Results were negative - i.e., peptide 16T did not downregulate the PDGF- α or β receptors.

Example 7

Studies were carried out to determine if the interaction of peptide 16T with PDGF receptors was agonistic or antagonistic. This involved the study of dimerization and autophosphorylation of PDGF and EGF receptors in intact cells.

Confluent human foreskin fibroblast cells were used (25 cm² dishes of cultures). The cells were washed twice with binding buffer, as described supra, with 1 mg/ml BSA added thereto. This was followed by 90 minutes of incubation with one of synthetic peptides 16, 16T, 20 and 20T on ice. This was followed by the addition of either PDGF-BB or EGF (300 ng/ml) and 60 minutes of further incubation. A dimerization assay was then carried out, basically following Eriksson et al., Growth Factors 6: 1-14 (1992). Essentially, receptors were cross linked for 20 minutes at room temperature in 1 mM BS³ (Bis(sulfosuccinimidyl)suberate) in lysis buffer (0.5% Triton X-100, 0.5% deoxycholate, 20 mM Hepes, pH 7.4, 150 mM NaCl, 10 mM EDTA, 1 mM PMSF (phenylmethylsulfonyl fluoride), 1% Trasylol (aprotinin), 100 μ M orthovanadate, a phosphatase inhibitor). Cross linking was quenched by adding 70 mM methylammonium chloride for 10 minutes. Samples were then subjected to SDS gel electrophoresis in 4% slab gels, followed by electroblotting on to nitrocellulose membranes. The blocked membranes were incubated for two hours with affinity purified phosphotyrosine antibodies (Ex et al., J. Biol. Chem. 259: 1145-1152 (1984)), followed by three washes. Blots were then incubated for 45 minutes with peroxidase conjugated, affinity purified swine antirabbit IgG immunoglobulin. After an additional three washes, complexes were visualized using the ECL developing system.

The results, presented in Figure 5, show that both PDGF and EGF induced autophosphorylation of receptors. After cross linking, most of the autophosphorylated receptors were visualized as fuzzy, double sized components (bracket of

16

Figure 5), probably representing dimers.

When peptide 16T was used, PDGF induced autophosphorylation and dimerization was inhibited by about 55%. There was no effect on EGF induced activity. Control peptide 20T showed no effect whatsoever. These results show that peptide 16T is an antagonist, rather than an agonist.

Example 8

Further experiments were carried out involving autophosphorylation and dimerization. These were more quantitative, as they used partially purified PDGF- β receptors.

A preparation of PDGF- β receptor, from Triton X-100 solubilized porcine uterus membranes and purified up to the Mono-Q chromatography step of Römstrand et al., J. Biol. Chem. 262: 2929-2932 (1987), was made, and the autophosphorylation assay described therein was carried out.

Approximately 100 ng of the receptor was incubated for 5 minutes at 0°C with peptide 16T or peptide 20, at different concentrations. PDGF-BB (100 ng) was added and incubated for another 15 minutes. Incubation mixtures had a total volume of 40 μ l and contained, as final concentration, 0.1% Triton X-100, 5% glycerol, 0.5 mM EGTA, 0.5 mM dithiothreitol, 20 mM Hepes, pH 7.4, 180 mM NaCl, 3 mM MnCl₂, and 1 mg/ml BSA. Four μ l of 150 μ M [³²P]ATP (containing 5 x 10⁶ cpm of radioactivity) was added, followed by an additional 10 minutes of incubation at 0°C. Incorporation of radioactivity was terminated by adding 5 μ l of 15 mM unlabelled ATP and 5 μ l of 40 mM phenylphosphate. Samples were cross linked by incubating with 0.5 mM DSS (12.5 mM, in dimethyl sulfoxide) for 30 minutes at room temperature. The cross linking reaction was blocked by adding 50 mM methylammonium chloride, 20 mM Hepes, pH 7.4.

In the absence of peptide, PDGF induced autophosphorylation of its 180 KDa receptor and a 130 KDa degradation product, as shown in Figure 5. Following covalent cross linking, most autophosphorylated material was seen as a double band at about 350 KDa.

When peptide 16T was present, as concentrations increased,

both dimerization and autophosphorylation decreased. Nearly complete inhibition was obtained at 5 μ g of peptide. Control peptide 20 showed no effect at concentrations up to 20 μ g. Peptide 16 had an intermediate effect, with complete inhibition at 20 μ g. These results parallel those obtained in the studies of ligand binding inhibition, discussed supra.

Example 9

Prior work has shown that each PDGF strand contains eight cysteine residues, but free SH groups have not been found. (Claesson-Welsh et al., Proc. Natl. Acad. Sci. USA 86: 4917-4921 (1989)). It was suspected that PDGF most probably contains an even number of interchain disulfide bridges, most likely two interchain bridges, and three intrachain bridges in each subunit. It was thought that interchain disulfide bridges might be more susceptible to reduction than the interchain disulfide bonds. In order to attempt to identify interchain bonds, partial reduction methodologies were employed.

Aliquots of recombinant PDGF-AA long splice variant were incubated with different concentrations of dithiothreitol ("DTT") for two hours at room temperature. These samples were then alkylated and analyzed by SDS-gel electrophoresis, using non reducing conditions. Silver staining followed.

Figure 6A shows that PDGF-AA gradually shifted from 30 KDa to 17 KDa - a shift from dimer to monomer - as the concentration of DTT increased. At 3 mM DTT, almost all PDGF appeared as a monomer, but the material migrated more slowly than fully reduced PDGF, suggesting the intrachain bonds remained.

This experiment confirmed that interchain bonds are more susceptible to reduction than intrachain bonds, and suggests that the use of this methodology could identify the particular residues involved.

Example 10

The experiment of Example 9 was carried out on a preparative scale. 90 μ g of recombinant, long splice PDGF-AA was treated with 3 mM DTT in 220 μ l of 0.36 M Tris.HCl pH 8.2 for two

hours at 20°C. This exposed interchain SH bonds, which were then reacted with 9 mM iodoacetic acid in the same solution for 15 minutes to alkylate the groups. The alkylated monomers were isolated by gel chromatography on Superose 12, (1 x 30 cm) in 6 M urea, 0.3 M NaCl and 1 M acetic acid at a flow rate of 15 ml/h. Two peaks eluted, as shown in Figure 6B. The fractions were analyzed via SDS-gel electrophoresis following Blobel et al., J. Cell Biol. 67: 835-851 (1975), followed by silver staining. The gel work showed that the two HPLC fractions were monomers and dimers. Monomeric material was isolated by desalting via reversed-phase HPLC using a narrow bore Brownlee Aquapore C1 column. The material was divided into two portions. One was used in receptor binding assays, the other was fully reduced. The experiments on these two fractions follow, those involving full reduction being presented first. Receptor binding was carried out using the protocols of Example 14, infra.

Example 11

The partially reduced, monomeric PDGF-A was fully reduced by 20 mM DTT in 4 M guanidine-HCl, 1 M Tris.HCl, pH 8.0 and 10 mM EDTA for two hours at 37°C. This fully reduces the monomers, which were then treated with 4-vinylpyridine (incubation for two hours, room temperature). The reduced monomers were desalted, as described supra and dried. The treatment with 4-vinylpyridine pyridylethylates cysteine residues, rendering them visible at 254 nm.

Reduced material was digested with Glu-C protease at an enzyme/substrate ration of 1/50 (w/w) for 15 hours at 37°C in 200 μ l of 2 M urea and 0.1 M ammonium bicarbonate. At the end of the reaction time, the mixture was applied to a Brownlee Aquapore C4 (2.1 x 30 mm) narrow bore column, and fragments were eluted by a linear gradient of n-propanol (0-27% over 60 minutes) 0.16% trifluoroacetic acid at a flow rate of 100 μ l/min. Effluent was monitored using a photodiode array detector, and spectral data were collected between 200 and 300 nm.

These HPLC fractions were dried onto polybrene treated glass

fiber discs and subjected to well known Edman degradation. HPLC information is presented in Figure 7A. The sequences which were found to contain cysteine residues are shown in Figure 7B (i.e., sequences SP1, 2, 3 and 4), as well as in SEQ ID NOS:

In Figure 7B, the "#" is a carboxymethyl cysteine, and "e" is a pyridylethyl cysteine.

Those cysteine residues involved in interchain disulfide bonds should appear as carboxymethyl cysteine, due to the action of iodoacetic acid, while intrachain bond forming cysteine should appear as pyridylethylcysteine. These results show that the 2nd and 4th cysteine residues in the PDGF-A monomer, form the interchain, disulfide bounds.

Example 12

In order to pursue the results of Example 11 further, cDNA sequence coding for a PDGF molecules were mutated so that Cys 123 and Cys 132 were serine. To do this, cDNA for the short splice version of PDGF-A (Betscholtz et al., Nature 320: 695-699 (1986)) was used. Following Kunkel et al., Meth. Enzymol 154: 367-382 (1987), codons corresponding to one or both of the residues, resulting in pSV Ser 2, pSV Ser 4, and pSV monoA were produced. A uracil containing template coding wild type PDGF-A was also produced. Similarly, corresponding codons in the B chain cDNA (Cys 124, Cys 133 of the PDGF B stop variant) were mutated to yield pSV monoB, together with conversion of codon 191 to a stop codon, thereby yielding a soluble product (Östman et al., Cell Reg. 2: 503-512).

To produce the vectors pSV monoA, pSVA Ser 2 and pSV Ser 4, mutated fragments were cloned into the EcoRI/Bal 1 sites of vector pSV-PDGF-A 102A (pSVA), as taught by Östman et al., J. Bio. Chem. 263: 16202-16208 (1988), in which wild type fragments were excised. The construct pSV monoB was generated by cloning into the EcoRI site of plasmid pSV7d. This plasmid is well known and its structure is given in Truett et al., DNA 4(8): 333-349 (1985), figure 2. It is also presented as Figure 12.

Example 13

The constructs of Example 12, including pSVA and pSVB stop were transfected into COS cells following Östman et al., Cell Reg. 2: 503-512 (1991), using 20 ug of plasmid DNA and 0.5 - 1x10⁶ cells in 60 mm culture dishes. Two days after transfection, metabolic labeling was performed. This was accomplished by growing cells overnight in 1.5 ml of cysteine free MCDB 104 medium, supplemented with 0.1 mCi [³⁵S] cysteine/ml, 10% dialyzed fetal calf serum, and antibiotics. After labelling, media were collected and cleared of cell debris via centrifugation. Cells were washed once in PBS, collected by scraping, and lysed in 0.5 ml of 0.5 M NaCl, 20 mM Tris-HCl, pH 7.5, 0.5% Triton X-100, 1% aprotinin, and 1 mM PMSF. Cell lysates were centrifuged for 15 minutes at 10,000 g, and supernatants subjected to immunoprecipitation using antiserum to PDGF-AA. Essentially, the samples were precleared by incubation with 15 ul of normal rabbit serum at 4°C for 1 hour, followed by addition of 60 ul of a 50% Protein-A-Sepharose slurry in PBS. This was incubated at 4°C for 30 minutes, and beads were removed by centrifugation. Following this, 15 ul of anti PDGF AA or anti-PDGF BB were added, followed by two hours of incubation at 4°C. This was again followed by incubation with Protein A Sepharose (supra). The beads were then washed five times with 0.5 M NaCl, 20 mM Tris, pH 7.5, 5 mg/ml BSA, 1% Triton X-100 and 0.1% SDS, as well as once with 20 mM Tris-HCl, pH 7.5. Immunocomplexes were eluted by adding 200 ul of nonreducing sample buffer, with three minutes of incubation at 95°C. Half of the eluted material was reduced by adding DTT (final concentration, 10 mM), and two minutes of incubation at 95°C. Alkylation was carried out with 50 mM final concentration iodoacetamide. Samples were analyzed by SDS gel electrophoresis, using 12-18% polyacrylamide gels and fluorography.

Results are shown in Figures 8A and 8B. Figure 8A shows that when conditioned medium from [³⁵S]-cysteine labelled cells was immunoprecipitated, only monomeric forms were found. When analyzed under reducing conditions, the PDGF mono A shifted in the gel, indicating that intrachain disulfide bonds

shifted in the gel, indicating that intrachain disulfide bonds were present. Also, anti-wild type PDGF-AA antiserum recognized the mono-A, supporting the theory that the conformation of PDGF mono A is similar to the two chains in the dimer.

The parallel mutant, PDGF mono B showed the same pattern of analysis, as will be seen in Figure 8B.

Example 14

The following experiments describe receptor binding assays using the recombinant proteins produced following Example 13.

In the case of recombinant proteins, thirty six hours after transfection, culture medium was changed to 1.5 ml of serum free medium, and culture continued for 48 hours. Media were then applied onto a narrow bore, reversed phase C4 HPLC column (2.1x30 mm) for desalting and concentration. The column was washed with 0.1% trifluoroacetic acid, and retained material eluted with 70% acetonitrile in 0.1% trifluoroacetic acid.

After evaporation, samples were dissolved in one tenth of the original volume of PBS, and binding to PDGF- α and β receptors was studied. The study was carried out by analyzing serial dilutions and their ability to compete with 125 I-PDGF-AA and 125 I-PDGF-BB for binding to AG-1518 cells. Cells had been

grown in Falcon 24-well plates to confluence, followed by one washing in binding buffer (PBS with 1 mg/ml BSA, 0.9 mM CaCl_2 , 0.5 mM MgCl_2). Cultures were incubated at 0°C for two hours in 200 μ l of binding buffer containing the different dilutions as shown in Figure 9, or known amounts of PDGF-AA or PDGF-BB for standardization. Cells were washed twice with binding buffer, after which radiolabelled PDGF-AA or PDGF-BB (0.5-2 ng; 15,000-30,000 cpm) in 200 μ l binding buffer was added.

This was incubated at 0°C for one hour, after which cells were washed five times with binding buffer, followed by lysis in 200 μ l of 20 mM Tris.HCl, pH 7.5, 1% Triton X-100 and 10% glycerol, at room temperature for 20 minutes. Solubilized 125 I radioactivity was measured in a geiger counter.

Where β -receptor assays were carried out, prior depletion as discussed *supra*, was also used.

The results, as presented in Figure 9, show monoB competed relatively well. Data are not shown for PDGF monoA, which did not detectably bind to the α receptor.

Example 15

It was important to determine whether the binding of monomeric PDGF to PDGF receptors induced agonistic or antagonistic effects. The PDGF-mono B molecule was therefore tested for its ability to activate β -receptor in an autophosphorylation assay. Conditioned media from cultures of COS cells transfected with pSV B stop, pSV monoB or from mock transfected cells were desalted and concentrated as described *supra*. A radioreceptor assay was carried out to determine receptor binding activity, using standard techniques. Once this was accomplished, media from pSV monoB or pSV monoB stop transfected cells were adjusted with mock transfected medium to receptor binding activity of 100 ng/ml. PAE cells expressing PDGF B receptors (Westmark et al., Proc Natl. Acad. Sci. USA 87: 128-132 (1990), grown in 25 cm^2 dishes were

labeled in serum and methionine free MCD8 104 medium supplemented with 0.1 mg/ml BSA and 0.1 ml [35 S] methionine/ml for three hours at 37°C. Cells were stimulated with 1 ml of different concentrations of conditioned media for 30 minutes at 4°C. A positive control was set up using 1 ml of mock transfected medium with 100 ng/ml of recombinant PDGF-BB.

Cells were washed once with PBS, scraped into a lysis buffer of 20 mM Tris.HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 0.5% deoxycholate, 0.5% Triton X-100, 30 mM pyrophosphate, 1% aprotinin and 1 mM PMSF, followed by centrifugation for 15 minutes at 10,000 g for clearance. Half of this lysate was incubated at 40°C for two hours with 5 μ l of antiserum against a peptide derived from the PDGF- β receptor (Claesson-Welsh et al., J. Biol. Chem. 264: 1742-1747 (1989)); the other half with 1 μ l of antiserum against phosphotyrosine (Ek et al., J. Biol. Chem. 259: 1145-1152 (1984)). Immunocomplexes were precipitated with 60 μ l of a 50% slurry of Protein-A-Sepharose in PBS, after which beads were washed three times with lysis buffer, twice with 20 mM Tris.HCl, pH 7.5, 0.5 M NaCl, 1%

buffer, twice with 20 mM Tris.HCl, pH 7.5, 0.5 M NaCl, 1% Triton X-100, and once in distilled water. Elution of immunocomplexes was performed by adding 100 μ l of sample buffer containing 4% SDS, 0.2 M Tris.HCl, pH 8.8, 0.5 M sucrose, 5 mM EDTA, 0.01% bromophenol blue and 2% mercaptoethanol. Immunocomplexes were analyzed by SDS-gel electrophoresis, using a 7% acrylamide gel and fluorography.

Figures 10A and 10B show these results. In Figure 10A, analysis of immunoprecipitates using SDS-gel electrophoresis shows that both pSVB stop and pSV monoB stimulated autophosphorylation. In order to determine whether PDGF-mono B caused dimerization of the receptor, the β receptor expressing PAE cells were labeled with [35 S] methionine and stimulated with concentrated conditioned media from COS cells transfected with either of the relevant constructs. In these experiments, the labeled PAE cells were incubated for 90 minutes at 4°C, with 1 ml portions of concentrated conditioned media from COS cells transfected with pSVB stop, pSV monoB or the mock transfectants. Cells were washed once with PBS and lysed in solubilization buffer containing 20 mM Hepes, pH 7.4, 100 mM NaCl, 0.5% Nonidet P40, 10% glycerol, 1 mM PMSF and 1% aprotinin for 20 minutes at 4°C, followed by centrifugal clearance (10,000 g, 30 minutes). Crosslinking was performed with 1 mM BS³ for 30 minutes at room temperature. Reaction was halted by incubation in 50 mM Tris.HCl, pH 7.5, for 10 minutes at room temperature. Immunoprecipitation and analysis was as above. Both PDGF mono B and PDGF-BB caused dimerization, as can be seen in Figure 10B.

Example 16

Experiments were carried out to determine the arrangement of the interchain disulfide bonds between the second and fourth cysteines. To do this two new mutants were constructed, i.e., PDGF A Ser 2 with the second residue mutated to a serine residue and PDGF A Ser 4 with the fourth residue mutated to a serine residue. COS cells were transfected with pSV(A), pSV A Ser 2, pSV A Ser 4, or both of pSV A Ser 2 and pSV A Ser 4. If interchain binding occurs

between corresponding cysteine residues (e.g., 2nd cysteine to 2nd cysteine, or 4th cysteine to 4th cysteine), then cells transfected with pSV A Ser 2 or pSV A Ser 4 alone will not form dimers. Indeed, dimerization should only occur in a co-transfectant.

Cells were labelled with [35 S] cysteine, conditioned medium or medium from mock-transfected COS cells was immunoprecipitated using anti-PDGF AA antiserum, and precipitates were analyzed via SDS-gel electrophoresis, with or without DTT, followed by fluorography.

Figure 11A shows that dimers were only found in the absence of DTT in the cotransfectants, showing that cross linkage was occurring. From this it can be concluded that the 2nd and 4th cysteine residues are disulphide bonded in crosswise fashion in the PDGF dimer.

Example 17

Tests were carried out to determine the activities of the transfectants described supra. Conditioned medium from the pSV A, pSV A Ser 2, pSV A Ser 4, and pSV A Ser 2 and pSV A Ser 4 transfectants were concentrated, desalted, and then combined with [125 I]-PDGF-AA to test for binding to the α receptor. Figure 11B shows that there was competition only in the presence of the co-transfectant. These experiments also demonstrate that PDGF dimers with a single interchain band are functionally active.

Example 18

A PDGF mutant was created which does not bind to the PDGF receptor, but which is sufficiently similar to wild type PDGF to undergo normal processing and dimerization. The mutant, referred to as PDGF-O, was prepared as follows. The vector pSV7d-PDGF-A, which codes for the short splice version of PDGF-A chain and is alluded to in example 12, supra (Betscholz et al., Nature 320: 695-699 (1986); see also Ostman et al., J. Biol. Chem. 263: 16202-16208 (1988)) was used. A 1.3 kilobase cDNA which codes for the short splice variant of PDGF-A was cloned into well known vector M13. Thereafter, mutagenesis was carried out in accordance with Kunkel et al., Meth.

25

was carried out in accordance with Kunkel et al., Meth. Enzymol. 154: 367-382 (1987), to substitute amino acids 156-162 by the corresponding amino acids of endothelial cell mitogen VEGF/VEGF, as described by Keck et al., Science 246: 1309-1312 (1989); Leung et al., Science 246: 1306-1309 (1989). The mutated DNA was then cloned into the vector pSV7d, as described by Truett et al., DNA 4: 333-349 (1985), and referred to in the prior examples. The resulting construct, referred to hereafter as pSV7d-PDGF-O, was subjected to routine DNA sequence analysis to verify that the sequence was correct. To summarize, the resulting construct pSV7d-PDGF-O coded for a short splice variant of PDGF-A wherein amino acids 156-162, i.e., EYVRKKP were replaced by KPHQGH. This choice was based upon several factors. First, the substituted sequence overlaps somewhat with one of two regions of the PDGF-B chain shown to bind to the PDGF-B receptor (Östman et al., J. Biol. Chem. 266: 10073-10077 (1991). Second, the region is hydrophilic, which suggests surface exposure on the molecule. Finally, it has been observed previously that there is perfect conservation of cysteine residues between PDGF and VEGF/VEGF, suggesting that the substituted sequences would not be expected to interfere with the overall protein structure.

Example 19

Following preparation of the vector described in Example 18, ^{supra}, the construct was used to transfect eukaryotic cells. The cell line COS-1, available from the American Type Culture Collection as ATCC (CRL 1650), was cultured in Dulbecco's minimum essential medium, supplemented with 10% fetal calf serum and antibiotics. The cells were transfected using the calcium phosphate method of Östman et al., Cell Regul 2: 503-512 (1991), using 10 µg samples of the construct, and 0.5-1x10⁶ cells per 60 mm dish. Parallel cultures were also set up, using pSV7d-PDGF-A. All cultures were metabolically labelled via addition of [³⁵S] cysteine to the medium, for 4 hours.

Following culture, conditioned medium was removed, and the cells were lysed. Both the media and the lysates were

26

subjected to immunoprecipitation experiments. These experiments used a polyclonal antiserum previously shown to recognize all PDGF-A isoforms (Heldin et al., Exp. Cell Res. 136: 255-261 (1981)). The immunoprecipitation took place overnight at 4°C. Protein A Sepharose CL-4B was used to collect the immunoprecipitates. These beads were incubated with the precipitate containing material for 45 minutes, after which they were washed four times with buffer (1% Triton X-100, 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mg/ml BSA, 0.1% SDS), and one time with 20 mM Tris-HCl, pH 7.5. The immune complexes were then eluted by heating the beads at 95°C for 4 minutes in buffer (4% SDS, 0.2 M Tris-HCl, pH 8.8, 0.5 M sucrose, 5 mM EDTA, 0.01% bromophenol blue). Some of the samples were also subjected to reduction treatment, using 10 mM dithiothreitol for two minutes at 95°C, followed by alkylation with 50 mM iodoacetamide.

Whether subjected to reducing or non-reducing conditions, all samples were then treated with SDS-gel electrophoresis in gels containing 14% polyacrylamide. Gels were soaked in "Amplify", and then exposed to Hyperfilm MP.

The results, presented in figure 13, show that pSV7d-PDGF-O produces a molecule which is processed to a secreted dimer having a molecular weight of about 30 kDa. This molecule, referred to hereafter as PDGF-OO (dimer) is similar in size to PDGF-AA. The monomer will be referred to hereafter as PDGF-O.

Example 20

Studies were carried out to determine the binding properties of the PDGF-OO homodimer. To do this, the conditioned media from the transfected cells (pSV7d-PDGF-O; pSV7d-PDGF-A), and mock transformed cells, were analyzed to determine if the secreted products competed with ¹²⁵I-PDGF-AA for binding to the PDGF-A receptor. The experiments used cell line AG1518, a human foreskin fibroblast line, passage 10-25 (obtained from the Human Genetic Mutant Cell Repository, Camden, N.J.). The cells were grown in 24 well plates, then rinsed one time in 0.5 ml binding buffer (PBS with 1 mg/ml BSA, 0.9 mM CaCl₂ and

0.5 mM MgCl₂), then incubated for two hours at 0°C with 125I-labelled PDGF-AA (2 ng/ml, 47,000 cpm/mg), together with one of unlabelled PDGF-AA (0-16 ng/ml), 24 hour conditioned medium from (a) mock transfectants, (b) pSV7d-PDGF-A transfectants, or (c) pSV7d-PDGF-O transfectants. Cultures were washed four times in ice cold binding buffer. The cell associated 125I radioactivity was extracted by incubation for 30 minutes at room temperature in 0.2 ml of 1% Triton X-100, 20 mM Tris-HCl, pH 7.5, and 10% (v/v) glycerol. The radioactivity was determined using a standard gamma-counter.

Figure 14 sets forth the results. The media from the pSV7d-PDGF-A transfectants contained about 150 ng/ml of PDGF-AA activity whereas no significant activity could be detected in the pSV7d-PDGF-O transfectant medium. This experiment demonstrates that the substitution of amino acids 156-162 of the PDGF-A chain with the corresponding sequences of VEGF/VPF leads to the loss of binding to the PDGF α receptor.

Example 21

Prior work by Beckmann et al., Science 241: 1346-1349 (1988), and Fleming et al., Proc. Natl. Acad. Sci. USA 86: 8063-8067 (1989), had shown that expression of human PDGF-B in NIH 3T3 cells lead to cell transformation by autocrine activation of endogenous PDGF receptors. Investigations were thus carried out to determine if, by expression of PDGF-O chain, transformed phenotypes could be reversed via formation of a PDGF-O heterodimer which would bind to the receptor but should not allow receptor dimerization.

To test this, NIH 3T3 cells which express PDGF-B chains (referred to hereafter as "sisT3"), were used. The cells were cotransfected with the pSV7d-PDGF-O construct described supra, and pSV2pac, a marker for puromycin resistance. The cells were transfected using the electroporation method of Westernmark et al., Proc. Natl. Acad. Sci. USA 87: 128-132 (1990), using 40 ug of pSV7d-PDGF-O and 1 ug of pSV2pac. Cells were selected 48 hours later by including 0.8 ug/ml of puromycin in the culture medium. The resistant clones were cultivated in medium supplemented with 0.5 ug/ml puromycin,

and 400 ug/ml of genitacin.

Approximately 20 resistant clones were then analyzed for PDGF-O production, using the immunoprecipitation method described supra.

As figure 15 shows, components of 40 and 24 kDa were detected in control cell lysates, and nothing was found in the media. About half of the puromycin resistant clones had new PDGF components, of about 30 kDa, in both lysate and medium. This does not conform to any known PDGF-BB homodimer. Studies discussed *infra* established it to be heterodimer PDGF-OB.

Example 22

In view of the results reported in Example 21, immunoprecipitation studies were carried out using PDGF-isoform specific antiserum. Such materials are described in, e.g., Thyberg et al., J. Cell Sci. 97: 219-229 (1990). In addition, antiserum against a peptide corresponding to amino acids 156-169 of PDGF-A (Hammacher et al., J. Biol. Chem. 263: 16493-16498 (1988)), was used.

The protocol for immunoprecipitation was exactly the same as that presented supra, with the exception that, prior to use of the peptide specific antiserum, cell culture medium of the sisT3 cells was treated with 10 mM dithiothreitol (DTT) for two hours at 37°C, followed by 50 mM iodoacetamide for 0.5 hours, at neutral pH and room temperature.

These results are given in figure 16.

When reducing conditions were used on three cell lines producing the 30 kDa material (so-called "Cl5", "Cl11" and "Cl18"), the anti-AA and anti-BB antiserum gave similar results. The precipitated material was the same size as materials precipitated by anti-AA from conditioned medium of a cell line which produces only PDGF-A, i.e., cell line AL72, as well as the materials precipitated from sisT3 using anti-BB antiserum. The recognition by the two antisera suggest that the 30 kDa material is a PDGF-OB heterodimer.

These experiments did not eliminate the possibility that a PDGF-AB heterodimer was formed, hence work with an antiserum against peptide 156-169 was carried out. In results not

depicted in the figures, the antiserum was found to bind the PDGF-A chain, but not PDGF-O produced by transfected COS cells. When the antiserum was tested against A172, components of 16, 17 and 23 kDa were found, i.e., three forms of PDGF-O.

5 A. No such forms were detected in the media from clones 5, 11 and 18.

The conclusion to be drawn from this work is that the 16, 17 and 23 kDa components which both anti-AA and anti-BB antiserum identify in the transfected sis3T3 cells are products of PDGF-O cDNA, and that these products are part of a PDGF-OB heterodimer in these transfectants.

Example 23

Once it had been established that the sis3T3 cells were producing PDGF-O and that the mutant was associating with PDGF-B to yield a PDGF-OB heterodimer, investigations were carried out to determine if the mutant affected the known, transformed phenotype of sis3T3 cells.

Three clones from the transfections described supra which did not produce PDGF-O ("C11", "C16", and "C19" hereafter), and three which did produce the molecule (the C15, C11 and C18 described supra), were compared. The comparison involved three parameters: cell morphology, growth rate, and colony formation in soft agar.

With respect to the first parameter, figure 17 compares the clones. The non producers (C11, 6, 19) were spindle shaped and exhibited criss cross growth patterns, both of which are typical of transformed cells. In contrast, C15, 11 and 18 had a well organized pattern of monolayer growth.

To assess the clones' growth rates, cells were cultured in Dulbecco's minimal essential medium (DMEM) augmented with 10% fetal calf serum over a 14 day period. Medium was changed at day 7. A graph of these experiments is shown in figure 18, representing mean values of duplicate experiments. The PDGF-O producers were growth arrested at day 7, and by day 14 showed a five fold decrease in number as compared to PDGF-O producing cells. There were no significant differences between the 3 clones within each group.

Colony formation in soft agar was studied by plating 5×10^4 cells/mg in 12 well dishes in 0.5 ml DMEM, supplemented with 10% FCS and 0.3% low gelling temperature agarose, either with or without 50 ng/ml PDGF-BB on top of a 0.5 ml layer of the same medium, with 0.6% low temperature agarose. The dishes were monitored for three weeks, after which they were microphotographed, and the cells were counted.

The cell count is presented below in Table 5. In addition, figure 19 shows the microphotograph mentioned supra. The PDGF-O negative clones formed anywhere from 87 to 124 colonies per 50,000 cells, while no colonies were found in the positive clones. When PDGF-BB was added, the PDGF-O producing cells did produce colonies at the same level as the negative cells, but the colonies were smaller. One concludes, therefore, that the PDGF-O expression blocked the ability of the sis producing cells to form colonies in soft agar. The formation of colonies in the presence of PDGF-BB clearly demonstrates that lack of colony formation is not due to a general loss of responsiveness to PDGF stimulation.

Table 5. Colony formation in soft agar of PDGF-O positive and negative sis3T3 clones

	PDGF-O positive clones			PDGF-O negative clones		
	5	11	18	1	6	19
vehicle	0	1	0	98	87	124
PDGF-BB (50 ng/ml)	104	85	76	N.D.	91	N.D.

The numbers represent colonies per 5×10^4 cells and are averages of triplicate

determinations, 1 S.D. < 0.14, N.D., not determined.

The experiments presented supra show that various peptides and modified peptides derived from PDGF chains act as antagonists and agonists to the PDGF molecule. Preferred antagonistic peptides contain epitopes from two regions of the PDGF-B chain. The resulting peptides have amino acid sequences which, however, are not found in either wild type PDGF monomer. A preferred family of such peptides can be represented by the formula

Ala Asn Phe Leu Val X(Y)n Glu Ile Val Arg Lys Lys Pro

where X is tryptophan or modified tryptophan, Y is any amino acid, and n is a whole number of 0 to 35. Especially preferred antagonists are the peptides referred to herein as "16" and "16T", having the amino acid sequence:

Ala Asn Phe Leu Val Trp Glu Ile Val Arg Lys Lys Pro

and

Ala Asn Phe Leu Val Xaa Glu Ile Val Arg Lys Lys Pro

respectively, where Xaa stands for thioanisolated tryptophan. Peptide 16T is far more efficient in competing with PDGF for receptor binding. The variant 16 NPS, in which tryptophan is coupled to 2-nitrophenylsulfenyl, is also more active as an antagonist than peptide 16. There is no immediate explanation for why these derivatives are superior to the original peptide 16, which is also active. The 13 amino acid sequence presented supra appears to be key to inhibitory/antagonistic activity. Further deletion of C-terminal amino acids, as indicated supra, resulted in insolubilization of the peptide,

and thus could not be evaluated. Truncation at the N-terminal end led to loss in activity.

Previous studies have shown that amino acids 105-144 of the B chain of PDGF are important for interacting with the B receptor (LaRochelle et al., Science 248: 1541-1544 (1990)). Additional studies have led to identification of Asn-115, Arg-154 and Ile-158 as important in binding (Östman et al., J. Biol. Chem. 266: 10073-10077 (1991)). The particularly preferred peptide 16 contains amino acids 116-121 and 157-163 of PDGF-B, and thus contains some amino acids close to those identified by Östman et al. as being important; however, it must be noted that the derivatives of the invention inhibit binding to both the α and β receptors, a property not recognized by the prior work in this field. Also, the evidence presented herein shows that even minor modifications in peptide structure have profound effect on antagonistic activity. The antagonistic effect of such peptides suggests their use in conditions characterized by excess or undesirable PDGF activity. These conditions include those discussed in the "background" section, supra, as well as chronic inflammatory conditions.

In connection with the observation on PDGF-B, it must be noted that other molecules, including vascular endothelial growth factor (vascular permeability factor or VEGF; see Keck et al., Science 246: 1309-1312 (1989); Leung et al., Science 246: 1306-1309 (1989)), and placental growth factor (Maglione et al., PNAS 88: 9267-9271 (1991)), show cysteine structures paralleling that of PDGF-B. The observations made herein suggest correlation to these other molecules, given the structural similarities.

While PDGF-A monomers were not nearly as active as the modified PDGF-B monomers, partially reduced, alkylated PDGF-A monomers did show some activity.

The examples set forth supra show, inter alia, that there is a specific pattern of cross-molecular binding which is involved in the formation of PDGF dimers. This observation can be exploited together with the observations regarding the

ability to form antagonistic dimeric molecules. For example, one can control production of heterodimeric PDGF-AB, where one of the chains has been modified to produce an antagonist. The recognition of a cross bond in the dimer enables one to produce forms of PDGF-AB exclusively, subject to the single restriction that the dimer only contains a single intermolecular bond. Co-transfection of a cell with a nucleic acid molecules coding for one monomer lacking cysteine at one of the second or fourth wild type positions, and a second molecule lacking the cysteine at the other listed wild type cysteine position guarantees high production of PDGF-AB. For example, if the first sequence codes for PDGF A without cysteine at the second position, and PDGF B without cysteine at fourth position, a dimer of PDGF-AB will still form, because the fourth cysteine of PDGF A can still bind the second position of PDGF B. On the other hand, dimeric PDGF AA will not form, because although the requisite fourth cysteine is present, the second cysteine is eliminated. Similar considerations dictate the absence of PDGF BB from such a system. One may, of course, produce homodimeric forms by cotransfection with nucleic acid sequences lacking the second cysteine and the fourth cysteine, but otherwise not modified. One may also transfect two separate cell samples, each with a different nucleic acid sequence, so that dimerization may occur, e.g., in the culture medium. Thus, one aspect of the invention is a kit for production of the dimers described ^{supra}, with separate nucleic acid portions coding for the desired monomer.

The invention thus encompasses antagonistic dimers produced in accordance with the principles herein, i.e., having only a single intermolecular disulfide bond. The amino acid positions described for the cysteine residues merely need modification, either by substitution by another amino acid, deletion, blocking, and so forth. It has been shown that such a PDGF AA molecule competes for binding. Antagonists could be designed from these molecules in which one of the chains is further modified to prevent binding to the receptor such as at

positions 156-162, e.g. This could then be directed to form a specific heterodimer with a wild type chain by virtue of modifying cysteine 2 or cysteine 4 in either molecule.

The foregoing disclosure also teaches the development of various amino acid containing molecules which function as antagonists to PDGF. Some of these molecules antagonize PDGF-A, and others PDGF-B. The antagonists may be monomer, or dimers. Of specific interest are those dimers which are joined by only a single cysteine bond, and molecules where the region defined by amino acids 156-162 of either PDGF-A or PDGF-B has been modified in some way. "Modified" as used herein is intended in its broadest sense, including total or partial deletion, and partial or total substitution by other amino acids. In connection with substitution by other sequence, the sequence KFHQGH is especially preferred. It must be noted, however, that the art is well aware of conservative substitutions for amino acids, and replacement of any or all of these amino acids by conservative substitution is embraced herein.

Those antagonists which contain the aforementioned modifications may be used in the form of monomers or dimers, the dimeric molecule referred to herein as "PDGF-08" being especially preferred. It must be noted, however, that the art is well aware of conservative substitutions for amino acids, and replacement of any or all of these amino acids by conservative substitution is embraced herein.

Those antagonists which contain the aforementioned modifications may be used in the form of monomers or dimers, the dimeric molecule referred to herein as "PDGF-08" being especially preferred. All such dimeric, PDGF antagonists are characterized by being able to bind to PDGF receptors and by inhibiting dimerization of these receptors. Receptor dimerization is necessary for PDGF activity, hence the antagonistic effect. The antagonists described herein may be made, e.g., via expression of the nucleic acid sequences which code for them. These sequences may be incorporated into expression vectors, such as plasmids, whereby the coding

sequences are operably linked to promoters. The expression vectors, as well as the nucleic acid sequences themselves, may serve as transfecting agents so as to produce cell lines which manufacture the antagonists. Eukaryotic cells, such as COS cells, are preferred.

It has been pointed out, *supra*, that the antagonists of the invention may be used in dimeric form. It is particularly preferred that when dimers are used, that one monomer be a normal PDGF monomer, and the other be modified. Such dimers can be produced recombinantly, by using host cells which produce one normal PDGF molecule and one modified molecule. One may produce the dimers via, e.g., cotransfection with appropriate nucleic acids, or via transfection of a cell which produces one normal PDGF molecule with nucleic acids coding for the second, modified molecule. Either PDGF-A or PDGF-B may serve as the normal monomer, and also as the modified monomer. One aspect of the invention is the provision of kits for enabling the artisan to make such dimers. In their broadest aspect, such kits include nucleic acid sequences for both PDGF monomers, preferably in the form of expression vectors. Such kits may also include additional reagents useful in transfection of cells, such as are known to the skilled artisan.

In addition to the other uses to which the antagonists of the invention may be put, as have been alluded to *supra*, the examples show that PDGF-B linked cell transformation may be relieved and reversed via administration of antagonists to PDGF-B. Thus, one aspect of the invention is a method for inhibiting an adverse effect of PDGF-B in a subject by administering a PDGF-B antagonist to the subject in an amount sufficient to inhibit the PDGF-B's effect. Cell transformation is one such adverse effect. Others are known to the artisan, such as those adumbrated in this application. Other aspects of the invention will be clear to the skilled artisan and do not require elaboration herein.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no

intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

(1) GENERAL INFORMATION:

(i) APPLICANT: Vassbotn, Fleming S., Anderson, Maria, Backstrom, Gudrun, Engström, Ulla, Heldin, Carl-Henrik, Hellmann, Ulf, Östman, Arne, Westermark, Bengt

(ii) TITLE OF INVENTION: PLATELET DERIVED GROWTH FACTOR ANTAGONISTS

(iii) NUMBER OF SEQUENCES: 11

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Felfe & Lynch
(B) STREET: 805 Third Avenue
(C) CITY: New York City
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10022

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: PC-DOS
(D) SOFTWARE: Wordperfect

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 07/977,234
(B) FILING DATE: 16-NOV-1992
(C) CLASSIFICATION: 514

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hanson, Norman D.
(B) REGISTRATION NUMBER: 30,946
(C) REFERENCE/DOCKET NUMBER: LUD 269.1

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 688-9200
(B) TELEFAX: (212) 638-3884

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ala Asn Phe Leu Val Trp Xaa Glu Ile Val Arg Lys Lys Pro
5 10

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ala Asn Phe Leu Val Xaa Xaa Glu Ile Val Arg Lys Lys Pro
5 10

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Ala Asn Phe Leu Val Trp Glu Ile Val Arg Lys Lys Pro
5 10

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Asn Phe Leu Val Xaa Glu Ile Val Arg Lys Lys Pro
5 10

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein

39

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ala Asn Phe Leu Val Xaa Pro Cys Val Glu Val Gln Leu Arg Pro 15
 5
 Val Gln Val Arg Lys Ile Gly Ile Val Arg Lys Lys Pro 25
 20

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Asn Phe Leu Val Trp Pro Cys Val Glu Val Gln Leu Arg Pro 15
 5
 Val Gln Val Arg Lys Ile Gly Ile Val Arg Lys Lys Pro 25
 20

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ser Ile Glu Glu Ala Val Pro Ala Val Cys Lys Thr Arg Thr Val Ile 15
 5
 Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro Thr Ser Ala Asn Phe Leu 30
 20

Ile Trp Pro Cys Val Glu Val Lys Arg Cys Thr Gly Cys Cys Asn 45
 35

Thr Ser Ser Val Lys Cys Gln Pro Ser Arg Val His His Arg Ser Val 60
 50

Lys Val Ala Lys Val Glu Tyr Val Arg Lys Lys Pro Lys Leu Lys Glu 80
 65
 Val Gln Val Arg Leu Glu Glu His Leu Glu Cys Ala Cys Ala Thr Thr 95
 85

Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp Thr Gly Arg Pro Arg Glu 110
 100

Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu Lys Pro Thr 125
 115

40

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Ser Ile Glu Glu Ala Val Pro Ala Val Cys Lys Thr Arg Thr Val Ile 15
 5

Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro Thr Ser Ala Asn Phe Leu 30
 20

Ile Trp Pro Cys Val Glu Val Lys Arg Cys Thr Gly Cys Cys Asn 45
 35

Thr Ser Ser Val Lys Cys Gln Pro Ser Arg Val His His Arg Ser Val 60
 50

Lys Val Ala Lys Val Glu Tyr Val Arg Lys Lys Pro Lys Leu Lys Glu 80
 65

Val Gln Val Arg Leu Glu Glu His Leu Gly Cys Ala Cys Ala Thr Thr 95
 85

Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp Thr Gly Arg Pro Arg Glu 110
 100

Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu Lys Pro Thr 125
 115

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Ser Ile Glu Glu Ala Val Pro Ala Val Xaa Lys Thr Arg Thr Val Ile 15
 5

Tyr Gly Ile Pro Arg Ser Gln Val Asp Pro Thr Ser Ala Asn Phe Leu 30
 20

Ile Trp Pro Cys Val Gly Val Lys Arg Xaa Thr Gly Xaa Xaa Asn 45
 35

Thr Ser Ser Val Lys Xaa Gln Pro Ser Arg Val His His Arg Ser Val 60
 50

Lys Val Ala Lys Val Glu Tyr Val Arg Lys Lys Lys Pro Lys Leu Lys Glu 65 70 75 80
 Val Gln Val Arg Leu Glu Glu His Leu Glu Xaa Ala Xaa Ala Thr Thr 85 90 95
 Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp Thr Gly Arg Pro Arg Glu 100 105 110
 Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu Leu Pro Thr 115 120 125

(2) INFORMATION FOR SEQ ID NO: 10:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Gly Tyr Val Arg Lys Lys Pro
 .. 5

(2) INFORMATION FOR SEQ ID NO: 11:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Lys Pro His Gln Gly Gln His
 .. 5

We claim:

1. Isolated amino acid containing antagonist for platelet derived growth factor.

2. The antagonist of claim 1 consisting of an amino acid sequence not found in either of PDGF A or PDGF B.

3. The antagonist of claim 2, having amino acid sequence Ala Asp Phe Leu Val X(Y)n Glu Ile Val Arg Lys Lys Pro wherein X is tryptophan or a modified tryptophan residue, Y is any amino acid and n is a number from 0 to 35.

4. The antagonist of claim 1, wherein said antagonist contains amino acid sequence:

Ala Asn Phe Leu Val X Glu Ile Val Arg Lys Lys Pro
 wherein X is tryptophan or a modified tryptophan residue.

5. The antagonist of claim 4, wherein X is thioanisolated tryptophan or a 2-nitro-phenylsulfenyl derivative.

6. The antagonist of claim 4, wherein said antagonist consists of amino acid sequence:

Ala-Asn-Phe-Leu-Val-X-Pro-Pro-Cys-Val-Glu-Val-Gln-
 Leu-Arg-Pro-Val-Gln-Val-Arg-Lys-Ile-Glu-Ile-Val-Arg-Lys-
 Lys-Pro

wherein X is tryptophan or a modified tryptophan residue.

7. The antagonist of claim 6, wherein X is thioanisolated tryptophan or a 2-nitro-phenyl sulfenyl chloride derivative.

8. Method for inhibiting binding of PDGF to a cell presenting a PDGF receptor comprising adding an amount of the antagonist of claim 1 to a sample containing said cell in an amount sufficient to inhibit binding of PDGF to said cell.

9. Isolated modified PDGF AA dimer, wherein at least one of amino acid 123 on either monomer or amino acid 132 on either monomer is not cysteine wherein said modified dimer is an antagonist for wild type PDGF AA.

10. The isolated modified PDGF AA dimer of claim 9, wherein amino acid 123 on one monomer and amino acid 132 on the second monomer are not cysteine.

11. Isolated modified PDGF BB dimer, wherein at least one of amino acid 124 on either monomer or amino acid 133 on either monomer is not cysteine wherein said modifier dimer is

an antagonist for wild type PDGF BB.

12. The isolated modified PDGF BB of claim 11, wherein amino acid 124 on one monomer and amino acid 133 on the second monomer are not cysteine.

13. Isolated dimer consisting of (i) a monomer of PDGF A or a monomer of PDGF B, and (ii) a non PDGF monomer, wherein said two monomers are connected by a single disulfide bond, wherein said dimer is a PDGF antagonist.

14. The isolated dimer of claim 13, wherein said non-PDGF monomer is a growth factor.

15. The isolated dimer of claim 13, wherein said non-PDGF monomer is VEGF.

16. The antagonist of claim 1, wherein said antagonist is a dimer.

17. The antagonist of claim 1, wherein said antagonist is a modified PDGF-A molecule.

18. The antagonist of claim 16, wherein said dimer comprises one modified PDGF-A molecule.

19. The antagonist of claim 18, wherein said modified PDGF-A molecule is modified at amino acid positions 156-162.

20. The antagonist of claim 19, wherein said modified PDGF-A molecule has amino acid sequence KPHQGQH at positions 156-162.

21. The antagonist of claim 1, wherein said antagonist is a modified PDGF-B molecule.

22. The antagonist of claim 16, wherein said dimer comprises one modified PDGF-B molecule.

23. The antagonist of claim 21, wherein said modified PDGF-B molecule is modified at amino acid positions 156-162.

24. The antagonist of claim 22, wherein said modified PDGF-B molecule is modified at amino acid positions 156-162.

25. The antagonist of claim 23, wherein said modified PDGF-B molecule has amino acid sequence KPHQGQH at positions 156-162.

26. The antagonist of claim 24, wherein said modified PDGF-B molecule has amino acid sequence KPHQGQH at positions 156-162.

27. The isolated antagonist of claim 16, wherein said dimer is a PDGF-AA dimer, with the proviso that at least one of amino acid 123 on either monomer or amino acid 132 on either monomer is not cysteine, and one of said monomers is modified at amino acid positions 156-162.

28. The isolated antagonist of claim 16, wherein said dimer has a single cysteine bond connecting the two monomers of said dimer.

29. The isolated antagonist of claim 28, wherein one of said monomers is a modified PDGF-A molecule.

30. The isolated antagonist of claim 29, wherein said PDGF-A monomer is modified at amino acids 156-162.

31. The isolated antagonist of claim 30, wherein said modified PDGF-A monomer has amino acids KPHQGQH at amino acid positions 156-162.

32. The antagonist of claim 18, wherein said dimer further comprises one PDGF-B molecule.

33. The antagonist of claim 19, wherein said dimer further comprises one PDGF-B molecule.

34. The antagonist of claim 20, wherein said dimer further comprises one PDGF-B molecule.

35. Isolated nucleic acid sequence which codes for the antagonist of claim 17.

36. Isolated nucleic acid sequence which codes for the antagonist of claim 19.

37. Isolated nucleic acid sequence which codes for the antagonist of claim 21.

38. Expression vector comprising the nucleic acid sequence of claim 35 operably linked to a promoter.

39. Expression vector comprising the nucleic acid sequence of claim 37 operably linked to a promoter.

40. Expression vector comprising the nucleic acid sequence of claim 36 operably linked to a promoter.

41. Expression vector of claim 40, designated pSV7d-PDGF-0.

42. Cell line transfected with the nucleic acid sequence of claim 35.

43. Cell line of claim 42, wherein said cell line is a eukaryotic cell line.
44. Cell line of claim 43, wherein said eukaryotic cell line is a COS cell line.
45. Cell line of claim 35, wherein said cell line produces PDGF-B.
46. Cell line of claim 45, wherein said cell line is transfected with a nucleic acid sequence which codes for PDGF-B.
47. Cell line transfected with a nucleic acid sequence which codes for the antagonist of claim 21.
48. Cell line of claim 47, wherein said cell line produces PDGF-A.
49. Cell line of claim 48, wherein said cell line is transfected with a nucleic acid sequence which codes for PDGF-A.
50. Kit useful in producing a PDGF antagonist, said kit comprising separate portions of a first and second nucleic acid sequence, each of which codes for a PDGF monomer, wherein one of said PDGF monomers is modified to inhibit binding to a PDGF receptor and the other PDGF monomer is a normal PDGF monomer.
51. The kit of claim 50, wherein said modified PDGF monomer is modified PDGF-A and said normal PDGF monomer is PDGF-B.
52. The kit of claim 51, wherein said modified PDGF monomer is modified PDGF-B and said normal PDGF monomer is PDGF-A.
53. The kit of claim 50, wherein said modified PDGF monomer is modified PDGF-A and said normal PDGF monomer is normal PDGF-A.
54. The kit of claim 50, wherein said modified PDGF monomer is modified PDGF-B and said normal monomer is normal PDGF-B.
55. The kit of claim 50, wherein said one of PDGF monomers is modified at amino acid positions 156-162.
56. Method for inhibiting adverse effects caused by PDGF-B in a patient comprising administering to said patient an amount of the antagonist of claim 1 in an amount sufficient to inhibit an adverse effect caused by PDGF-B.

57. The method of claim 56, wherein said adverse effect is cell transformation.
58. The method of claim 56, wherein said antagonist is PDGF-OB.
59. Isolated platelet derived growth factor agonist having the amino acid sequence of PDGF-B monomer with the proviso that residues 124 and 133 are not cysteine.
60. The isolated platelet derived growth factor agonist of claim 59, wherein at least one of residues 124 and 133 is serine.
61. The isolated platelet derived growth factor agonist of claim 59, wherein both of residues 124 and 133 are serine.
62. Isolated platelet derived growth factor agonist having the amino acid sequence of PDGF-A monomer with the proviso that residues 123 and 132 are not cysteine.
63. The isolated platelet derived growth factor agonist of claim 62, wherein at least one of amino acids 123 and 132 is serine.
64. The isolated platelet derived growth factor agonist of claim 62, wherein both of amino acids 123 and 132 are serine.
65. Isolated nucleic acid molecule coding for the agonist of claim 59.
66. Isolated nucleic acid sequence coding for the agonist of claim 62.
67. Plasmid containing the isolated nucleic acid sequence of claim 65.
68. Plasmid containing the isolated nucleic acid sequence of claim 66.
69. Kit useful in production of a PDGF dimer having a single intermolecular disulfide bond, comprising separate portions of a first and a second nucleic acid sequence, each of which codes for a PDGF monomer, wherein one of said first and second nucleic acid molecules is modified to not code for a cysteine at the second or fourth cysteine portion of a normal PDGF monomer.
70. The kit of claim 69, wherein the one said first and second nucleic acid molecules has been modified to not code

47

for a cysteine at the second cysteine position of a normal PDGF monomer, and the second of said nucleic acid molecules has been modified to not code for a cysteine at the fourth cysteine position of a normal PDGF monomer.

5 71. The kit of claim 69, wherein said first and second nucleic acid molecules code for PDGF A.

72. The kit of claim 69, wherein said first and second nucleic acid molecules code for PDGF B.

10 73. The kit of claim 69, wherein one of said first and second nucleic acid molecules codes for PDGF A, and the other of said first and second nucleic acid molecules codes for PDGF B.

74. Cell line transfected with the isolated nucleic acid molecule of claim 65.

15 75. Cell line transfected with the isolated nucleic acid molecule of claim 66.

76. Method for enhancing PDGF effect on a cell comprising administering an amount of the PDGF agonist of claim 59 sufficient to enhance effect of PDGF thereon.

20 77. Method for enhancing PDGF effect on a cell comprising administering an amount of the PDGF agonist of claim 60, sufficient to enhance effect of PDGF thereon.

78. Isolated PDGF AA dimer, wherein at least one of amino acid 123 on either monomer or amino acid 132 on either monomer is not cysteine.

79. The isolated PDGF AA dimer of claim 78, wherein amino acid 123 on one monomer and amino acid 132 on the second monomer are not cysteine.

30 80. Isolated PDGF BB dimer, wherein at least one of amino acid 124 on either monomer or amino acid 133 on either monomer is not cysteine.

81. The isolated PDGF BB of claim 80, wherein amino acid 124 on one monomer and amino acid 133 on the second monomer are not cysteine.

35 82. Isolated dimer consisting of (i) a monomer of PDGF A or a monomer of PDGF B, and (ii) a non PDGF monomer, wherein said two monomers are connected by a single disulfide bond.

48

83. The isolated dimer of claim 82, wherein said non-PDGF monomer is a growth factor.

84. The isolated dimer of claim 82, wherein said non-PDGF monomer is VEGF.

5

AMENDED CLAIMS

[received by the International Bureau on 7 September 1993 (07.09.93); original claims 1-84 replaced by amended claims 1-43 wherein original claims 1, 2, 16-18, 21, 22, 24, 26, 28, 29, 32-40, 42-54, 62-64, 66, 68-73, 75 and 77-84 are cancelled and new claims 6-8, 22-28, 30, 37 and 39-42 are added (5 pages)]

1. Isolated peptide antagonist for platelet derived growth factor, consisting of amino acid sequence
Ala Asp Phe Leu Val Xaa Xaa Glu Ile Val Arg Lys Lys Pro
wherein the first Xaa is tryptophan or modified tryptophan,
and the second Xaa is anywhere from 0 to 35 amino acids.
2. The antagonist of claim 1, wherein the second Xaa is 0 amino acids.
3. The antagonist of claim 1 or 2, wherein the first Xaa is tryptophan, thioanisolated tryptophan, or a 2-nitrophenyl sulfonyl chloride derivative of tryptophan.
4. The antagonist of claim 1, wherein the second Xaa is Pro Pro Cys Val Glu Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile.
5. The antagonist of claim 4, wherein the first Xaa is thioanisolated tryptophan or a 2-nitrophenylsulfonyl tryptophan derivative.
6. The antagonist of any of claim 1, 2, 3 or 4 wherein the first Xaa is tryptophan.
7. Isolated nucleic acid molecule which codes for the antagonist of claim 6.
8. Expression vector comprising the isolated nucleic acid of claim 7, operably linked to a promoter.
9. Method for inhibiting PDGF binding to a cell which presents PDGF α and PDGF β receptors, comprising contacting said cell with an amount of the antagonist of any of claim 1, 2, 3, 4, 5 or 6, in an amount sufficient to prevent binding of PDGF B to said cell.

10. Isolated modified PDGF AA dimer, wherein at least one of amino acid 123 on either monomer or amino acid 132 on either monomer is not cysteine wherein said modified dimer is an antagonist for wild type PDGF AA.

11. The isolated modified PDGF AA dimer of claim 109, wherein amino acid 123 on one monomer and amino acid 132 on the second monomer are not cysteine.

12. Isolated modified PDGF BB dimer, wherein at least one of amino acid 124 on either monomer or amino acid 133 on either monomer is not cysteine wherein said modifier dimer is an antagonist for wild type PDGF BB.

13. The isolated modified PDGF BB of claim 12, wherein amino acid 124 on one monomer and amino acid 133 on the second monomer are not cysteine.

14. Isolated dimer consisting of (i) a monomer of PDGF A or a monomer of PDGF B, and (ii) a non PDGF monomer, wherein said two monomers are connected by a single disulfide bond, wherein said dimer is a PDGF antagonist.

15. The isolated dimer of claim 14, wherein said non-PDGF monomer is a growth factor.

16. The isolated dimer of claim 14, wherein said non-PDGF monomer is VEGF.

17. Isolated peptide consisting of a PDGF monomer modified at amino acid positions 156-162.

18. The isolated peptide of claim 17, having an amino acid sequence KPHQGQG at positions 156-162.

19. The isolated peptide of claim 17 or 18 wherein said monomer is PDGF A.

20. The isolated peptide of claim 17 or 18, wherein said monomer is PDGF-B.

21. Isolated dimer consisting of:

- (i) one of PDGF-A or PDGF-B, and
- (ii) the isolated peptide of any of claim 17, 18, 19 or 20.

22. Isolated dimer consisting of two modified PDGF-A monomers, wherein one of said monomers is modified so that at least one of amino acids 123 and 132 is not cysteine, and one of said monomers is modified at amino acid positions 156-162.

23. Isolated dimer consisting of two modified PDGF-B monomers, wherein one of said monomers is modified so that at least one of amino acids 124 and 133 is not cysteine, and one of said monomers is modified at amino acid positions 156-162.

24. The dimer of either of claims 22 or 23, wherein the monomer modified at positions 156-162 has amino acids KPHQCQH at said positions.

25. Isolated dimer consisting of:

- (i) one of (a) PDGF-A modified at at least one of amino acid positions 123 and 132, so that said at least one of said positions is not cysteine and (b) PDGF-B modified at at least one of amino acid positions 124 and 133 so that said at least one of said positions is not cysteine, and
- (iii) the isolated peptide of any of claims 17, 18, 19 or 20.

26. Cell line transfected with the nucleic acid molecule of claim 7 or the expression vector of claim 8.

27. The cell line of claim 26, wherein said cell line is also transfected with a nucleic acid molecule which codes for any of PDGF-A and PDGF-B.

28. The cell line of claim 26, wherein said cell line produces at least one of PDGF-A or PDGF-B.

29. Kit useful in producing the dimer of any of claims 21, 22, 23, 24, or 25 comprising a pair of nucleic acid molecules, each of which codes for a monomer of said dimer.

30. Isolated nucleic acid molecule which codes for the peptide of claim 17, 18, 19 or 20.

31. Isolated platelet derived growth factor agonist consisting of a modified PDGF-B monomer wherein amino acids 124 and 133 are not cysteine.

32. The isolated agonist of claim 31, wherein each of the amino acids at positions 124 and 133 is serine.

33. The isolated agonist of claim 31, wherein one of the amino acids at positions 124 and 133 is serine.

34. Isolated nucleic acid molecule which codes for the agonist of claim 31, 32 or 33.

35. Plasmid which codes for the agonist of claim 31, 32 or 33.

36. Cell line transfected with the isolated nucleic acid molecule of claim 34 or the plasmid of claim 35.

37. Expression vector comprising the isolated nucleic acid molecule of claim 30, operably linked to a promoter.

38. The expression vector of claim 37, designated pSV7d-PDGF-O.

39. Cell line transfected with the nucleic acid molecule of claim 31 or the expression vector of claim 37 or 37.

40. Method for inhibiting adverse effects caused by PDGF-B comprising administering an amount of the antagonist of claim 25 to a patient in need thereof to inhibit an adverse effect caused by PDGF-B.


41. The method of claim 41, wherein said adverse effect is cell transformation.

42. The method of claim 40 or 41, wherein said antagonist PDGF0B.

43. Method for enhancing PDGF effect on a cell comprising administering an amount of the PDGF agonist of claim 31 to a cell in an amount sufficient to enhance PDGF effect on said cell.


1/23

FIG. 1



SUBSTITUTE SHEET

FIG. 2



SUBSTITUTE SHEET

FIG. 3A






FIG. 3B






SUBSTITUTE SHEET

4/23



5/23



SUBSTITUTE SHEET

SUBSTITUTE SHEET

FIG. 6




FIG. 6A






FIG. 5


SUBSTITUTE SHEET

9/23



SUBSTITUTE SHEET

FIG. 6B



SUBSTITUTE SHEET

10/23

11/23

FIG. 7B

SIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWP
sp4 -----
sp3 -----
PCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKE
sp1 -----
sp2 -----
YVRKKPKLKEVQVRLEEHLECACATTSLNPDYREE
sp2 @ - @ - - - - -
DTGRPRESGKKRKRRLKPT

FIG. 8A





FIG. 8B




SUBSTITUTE SHEET

SUBSTITUTE SHEET

13/23

12/23

FIG. 9



SUBSTITUTE SHEET




FIG. 10A




FIG. 10B

SUBSTITUTE SHEET

14/23

15/23

FIG. 11A

FIG. 11B





FIG. 12




SUBSTITUTE SHEET

SUBSTITUTE SHEET


17/23

FIG. 14





16/23

FIG. 13




SUBSTITUTE SHEET

SUBSTITUTE SHEET



21/23

FIG. 18



SUBSTITUTE SHEET

20/23




FIG. 17F




FIG. 17E




FIG. 17D



FIG. 17C



FIG. 17B



FIG. 17A

SUBSTITUTE SHEET




FIG. 19I



FIG. 19H




FIG. 19G

SUBSTITUTE SHEET




FIG. 19F




FIG. 19E




FIG. 19D

SUBSTITUTE SHEET



FIG. 19C




FIG. 19B




FIG. 19A

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04550

A. CLASSIFICATION OF SUBJECT MATTER

IPC Cl. : A61K 37/02, 37/26; C12N 15/00, 15/12, 15/18
US Cl. : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 43577.2, 69.1, 69.4, 172.3, 240.2, 252.3, 320.1; 5142, 12; 530/250, 351, 399; 530/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and DIALOG (files 5, 155, 351, 357, 358) search terms: PDGF, dimer, homodimer, heterodimer, cysteine, disulfide, A-chain, B-chain, antigenic, agonist.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ₁ P Y ₁ P	WO, A, 92/11364 (PANG) 09 JULY 1992, see entire document.	1, 2, 8, 16-18, 35, 38, 42-43, 50, 53, 3, 44
X ₁ P	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 267, Number 16, issued 05 June 1992, M. Andersson et al., "Assignment of Interchain Disulfide Bonds in Platelet-derived Growth Factor (PDGF) and Evidence for Agonist Activity of Monomeric PDGF," pages 11260-11266, see entire document.	1-3, 9-10, 16, 28, 50, 53
Y	US, A, 4,959,314 (MARK ET AL.) 25 September 1990, see entire document.	78-81

Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	Enter document number in the international filing date or priority date and enter the number of the international filing date or priority date in the continuation of Box C.
* "A" Document defining the general state of the art which is considered to be prior art for the purposes of the invention	Document defining the general state of the art which is considered to be prior art for the purposes of the invention
* "B" Document defining the general state of the art which is considered to be prior art for the purposes of the invention	Document defining the general state of the art which is considered to be prior art for the purposes of the invention
* "C" Document which may have priority claims or which is cited in the international filing date or which is cited in the national filing date or which is cited in the special request (as specified)	Document which may have priority claims or which is cited in the international filing date or which is cited in the national filing date or which is cited in the special request (as specified)
* "D" Document referring to an oral disclosure, use, exhibition or other means	Document referring to an oral disclosure, use, exhibition or other means
* "E" Document published prior to the international filing date but later than the priority date claimed	Document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

15 June 1993

Date of mailing of the international search report

09 AUG 1993

Name and mailing address of the ISAUS
Office of Patent and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
MARIANNE PORTALLEN*Marianne PortalLEN*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04550

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,845,075 (MURRAY ET AL.) 04 July 1989, see entire document.	80-81
Y	US, A, 4,889,919 (MURRAY ET AL.) 26 December 1989, see entire document.	78-79
Y,P	ONCOGENE, Volume 8, Number 3, issued March 1993, D.W. Maher et al., "Alanine mutagenesis of conserved residues in the platelet-derived growth factor family: identification of residues necessary for dimerization and transformation," pages 533-541.	1-3, 11-12, 16, 21-24, 28, 47, 50, 54-55
X ₁ Y	MOLECULAR AND CELLULAR BIOLOGY, Volume 8, Number 3, issued March 1988, M.K. Sauter et al., "Identification of Nonessential Disulfide Bonds and Altered Conformations in the v-src Protein, a Homolog of the B Chain of Platelet-Derived Growth Factor," pages 1011-1018, see entire document.	80-81 1-3, 11-12, 16, 21-22, 28, 37, 39, 47, 50, 54, 56-61, 65, 67, 69, 72, 74, 76-77
Y,P	THE EMBO JOURNAL, Volume 11, Number 11, issued November 1992, C. Oefner et al., "Crystal structure of human platelet-derived growth factor BB," pages 3921-3926, see entire document.	78-81
Y	SCIENCE, Volume 236, issued 05 June 1987, N.A. Giese et al., "The Role of Individual Cysteine Residues in the Structure and Function of the v-src Gene Product," pages 1315-1318, see entire document.	1-3, 11-12, 16, 21-22, 28, 37, 39, 47, 50, 54, 56-61, 65, 67, 69, 72, 74, 76-77, 80-81
Y	BIOCHEMISTRY, Volume 30, Number 13, issued 02 April 1991, M. Jaumann et al., "On the Structure of Platelet-Derived Growth Factor AA: C-Terminal Processing, Epitopes, and Characterization of Cysteine Residues," pages 3303-3309, see entire document.	1-3, 9-10, 16-18, 28-29, 52-53, 62-64, 66, 68-69, 71, 75, 78-79
Y,P	BIOCHEMISTRY, Volume 32, Number 9, issued 09 March 1993, M. Hanu et al., "Disulfide Bonds in Recombinant Human Platelet-Derived Growth Factor BB Dimer: Characterization of Intermolecular and Intramolecular Disulfide Linkages," pages 2431-2437, see entire document.	78-81

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04550

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(Telephone Practice)
Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ This additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet)(1)/July 1992

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04550

A. CLASSIFICATION OF SUBJECT MATTER:
US CL. :

4357.2, 69.1, 69.4, 172.3, 240.2, 252.3, 320.1; 530330, 351, 399; 5142, 12; 536723.5

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

- I. Claims 1-34, 59-64, and 78-84, drawn to PDGF antagonists, a first composition, and a method of inhibiting binding, a first method of use, classified in Class 530334, for example.
- II. Claims 35-55 and 65-75, drawn to DNA molecules, vectors, transformed host cells, and kits, classified in Class 536723.5, for example.
- III. Claims 56-58, drawn to a method for inhibiting adverse PDGF effects, classified in Class 51412, for example.
- IV. Claims 76-77, drawn to a method for enhancing PDGF effects, classified in Class 4357.1, for example.

Form PCT/ISA/210 (extra sheet)(July 1992)